Deep Health AI India Shareholders OK ₹50 Crore Capital Increase

Deep Health AI India Limited shareholders have approved a plan to raise the company's authorized share capital from ₹15 crore to ₹50 crore. This significant increase, confirmed through a postal ballot, provides the company with greater financial flexibility for future strategic initiatives as it continues its shift towards becoming an AI-driven healthcare provider.

Key Developments

Shareholders voted to approve an ordinary resolution to increase the company's authorized share capital. The change moves the capital limit from ₹15 crore up to ₹50 crore. This requires amendments to the company's Memorandum of Association. The decision was formalized via a postal ballot process, including remote e-voting, with results based on a Scrutinizer's Report dated March 28, 2026.

Why This Matters

The boost in authorized share capital grants Deep Health AI India enhanced financial maneuverability. This move prepares the company for potential future equity issuances, strategic acquisitions, or other capital-intensive projects crucial for its expansion plans in the artificial intelligence and healthcare technology sector.

Company Background

Deep Health AI India Limited, formerly known as Deep Diamond India Limited, has been undergoing a significant strategic transformation. The company officially changed its name on February 17, 2026, to reflect its new focus on artificial intelligence and healthcare technology.

In November 2025, the company launched its AI-driven wellness platform, 'Deep Health India AI,' which uses facial scan technology for preventive health insights. This diversification aims to capture a share of India's growing digital health market.

However, the company has faced scrutiny over its fund utilization. Auditors noted that proceeds from a ₹39.98 crore rights issue in October 2025 were largely diverted to equity investments instead of the planned acquisition of Oasis Ceramics Private Limited. This has led to funding delays and requests for extensions from the National Company Law Tribunal (NCLT) for the acquisition.

Impact of the Vote

The shareholder approval empowers Deep Health AI India to increase its borrowing and issuance capacity. The company's Memorandum of Association will be updated to reflect the higher authorized share capital. This financial step is designed to enable the company to pursue growth opportunities more aggressively.

Potential Risks

The company faces execution risk as it transitions from a legacy jewelry business to an AI health-tech firm. Past issues with fund diversion from a rights issue and acquisition delays point to potential governance and financial execution challenges. The successful deployment of any future capital raised will be critical for realizing the company's transformation objectives.

Competitive Landscape

Deep Health AI India's approach of using AI-powered facial scans for preventive wellness sets it apart. Competitors like Qure.ai and Niramai Health Analytix primarily focus on AI for medical imaging and diagnostics. Broader technology firms such as Tata Elxsi are involved in AI across various sectors, including healthcare. While these peers concentrate on specific diagnostic tasks, Deep Health AI aims for broader accessibility in preventive health screening.

Next Steps

Investors will look for confirmation of the formal increase in authorized share capital with regulatory bodies. Announcements detailing how the company plans to use this enhanced financial flexibility for strategic initiatives or funding will also be key. Additionally, updates on the progress of the Oasis Ceramics acquisition and any further NCLT proceedings will be closely monitored.